Article
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
BMC cancer - 23 Aug 2021
Nishizawa Yujiro, Haraguchi Naotsugu, Kim Hirotoshi, Ide Yoshihito, Nakata Ken, Okamura Shu, Kudo Toshihiro, Satoh Taroh, Uemura Mamoru, Matsuda Chu, Mizushima Tsunekazu, Murata Kohei, Doki Yuichiro, Eguchi Hidetoshi
Abstract excerpt
BACKGROUND: Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated. This study aimed to compare S-1 and oxaliplatin (SOX) + bevacizumab (B-mab) with SOX + cetuximab (C-mab) in patients with previously untreated recurrent advanced CRC with wild-type KRAS. METHODS: This randomized phase II, open-label,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.